PLATELET MEMBRANE GLYCOPROTEIN III (GPIII) IS KNOWN TO BE THE LOCUS FOR THE PLATELET ALLOANTIGEN PLA1.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$44,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4984
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Imbic Inc
Po Box 7539, Columbia, MO, 65205
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MARK E SMITH
PRINCIPAL INVESTIGATOR
(314) 874-2481
Business Contact:
() -
Research Institution:
n/a
Abstract
PLATELET MEMBRANE GLYCOPROTEIN III (GPIII) IS KNOWN TO BE THE LOCUS FOR THE PLATELET ALLOANTIGEN PLA1. THIS ANTIGEN IS A GENE PRODUCT OF ONE ALLELE OF A BI-ALLELIC SYSTEM HAVING THE OBSERVED DISTRIBUTION OF: PLA1A1=0.69; PLA1A2= 0.28; AND PLA2A2=0.03. EXPOSURE TO THE PLA1 ANTIGEN CAN INDUCE ALLOIMMUNIZATION IN PLA2A2 INDIVIDUALS AFTER PLATELETTRANSFUSIONS OR DURING PREGNANCY IN PLA2A2 MOTHERS CARRYING PLA1A2 INFANTS. THIS ALLOIMMUNIZATION PRODUCES ANTI-PLA1 ANTIBODIES WHICH CAN RESULT IN SEVERE THROMBOCYTOPENIA IN BOTH POST-TRANSFUSION PURPURA OR IN IMMUNE NEONATAL THROMBO-CYTOPENIA. SINCE A LARGE FRACTION OF THE POPULATION IS PLA1A1, THEY MAY, IN A SIMILAR MANNER, DEVELOP ALLOANTI- BODIES TO THE PLA2 ANTIGEN. THIS PROCESS MAY ACCOUNT FOR PATIENTS WHO BECOME REFRACTORY TO PLATELET TRANSFUSION DURING PLATELET SUPPORT THERAPY AND WHO SHOW EVIDENCE OF PLATELET-SPECIFIC ANTIBODIES UNRELATED TO ANTI-HLA SENSITI- ZATION. THEREFORE, THERE IS A SIGNIFICANT CLINICAL USE FOR A SYSTEM WHICH CAN DETECT THE PRESENCE OF THESE SPECIFIC ANTI-PLATELET ANTIBODIES AND DETERMINE THE PHENOTYPE OF RECIPIENTS OF PLATELET TRANSFUSIONS AND OF EXPECTANT MOTHERS. A NEW, SIMPLE, SPECIFIC ASSAY TECHNIQUE FOR DETECTION OF THE ANTI-PLA1 OR -PLA2 ANTIBODIES IN PATIENT SERA HAS BEEN DEVELOPED; USING THE SAME TECHNOLOGY, AN ASSAYFOR QUANTITATION OF THESE TWO ANTIGENS ON PLATELET SURFACES TO DETERMINE THE PLATELET PLA1/A2 PHENOTYPE WAS ESTABLISHED.BOTH ASSAYS USE LABELED, PURIFIED GPIII IN A QUANTITATIVE IMMUNOPRECIPITATION ASSAY. THE PHASE I PLAN OF THIS PRO- POSAL WILL DEVELOP THIS ASSAY INTO A BIOTIN-AVIDIN LINKED SYSTEM HAVING A FORMAT COMPATIBLE WITH EXPANSION TO A COMMERCIAL KIT. PHASE II OF THE PROJECT WOULD INVOLVE DEVELOPMENT OF THIS ASSAY SYSTEM TO AN INEXPENSIVE KIT FORM AND PRODUCTION FOR USE IN CLINICAL EVALUATION.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government